384 related articles for article (PubMed ID: 26825871)
1. Activation of mTORC1 in B Lymphocytes Promotes Osteoclast Formation via Regulation of β-Catenin and RANKL/OPG.
Xu S; Zhang Y; Liu B; Li K; Huang B; Yan B; Zhang Z; Liang K; Jia C; Lin J; Zeng C; Cai D; Jin D; Jiang Y; Bai X
J Bone Miner Res; 2016 Jul; 31(7):1320-33. PubMed ID: 26825871
[TBL] [Abstract][Full Text] [Related]
2. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
3. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
4. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.
Kwan Tat S; Pelletier JP; Lajeunesse D; Fahmi H; Lavigne M; Martel-Pelletier J
Clin Exp Rheumatol; 2008; 26(2):295-304. PubMed ID: 18565252
[TBL] [Abstract][Full Text] [Related]
5. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
6. Osteoclast differentiation by RANKL and OPG signaling pathways.
Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
[TBL] [Abstract][Full Text] [Related]
7. Dominant negative N-cadherin inhibits osteoclast differentiation by interfering with beta-catenin regulation of RANKL, independent of cell-cell adhesion.
Shin CS; Her SJ; Kim JA; Kim DH; Kim SW; Kim SY; Kim HS; Park KH; Kim JG; Kitazawa R; Cheng SL; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2200-12. PubMed ID: 16294273
[TBL] [Abstract][Full Text] [Related]
8. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
9. Naringin increases osteoprotegerin expression in fibroblasts from periprosthetic membrane by the Wnt/β-catenin signaling pathway.
Yang C; Liu W; Zhang X; Zeng B; Qian Y
J Orthop Surg Res; 2020 Dec; 15(1):600. PubMed ID: 33302980
[TBL] [Abstract][Full Text] [Related]
10. The function and meaning of receptor activator of NF-κB ligand in arterial calcification.
Nie B; Zhou SQ; Fang X; Zhang SY; Guan SM
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):666-671. PubMed ID: 26489619
[TBL] [Abstract][Full Text] [Related]
11. Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis.
Ainola M; Mandelin J; Liljeström M; Konttinen YT; Salo J
Clin Exp Rheumatol; 2008; 26(2):240-6. PubMed ID: 18565244
[TBL] [Abstract][Full Text] [Related]
12. [RANKL and OPG expression in bone marrow-derived mesenchymal stem cells of ovariectomied promotes osteoclast development and enhances its function].
Shao B; Yu Y; Fu X; Xue H; Qi M; Shuai Y; Zhou Z; Jin Y; Yang D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Dec; 29(12):1262-6. PubMed ID: 24321069
[TBL] [Abstract][Full Text] [Related]
13. Antiresorptive activity of osteoprotegerin requires an intact heparan sulfate-binding site.
Li M; Xu D
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17187-17194. PubMed ID: 32636266
[TBL] [Abstract][Full Text] [Related]
14. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption.
Xiong L; Jung JU; Wu H; Xia WF; Pan JX; Shen C; Mei L; Xiong WC
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3487-92. PubMed ID: 25733894
[TBL] [Abstract][Full Text] [Related]
15. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
16. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.
Ozaki Y; Koide M; Furuya Y; Ninomiya T; Yasuda H; Nakamura M; Kobayashi Y; Takahashi N; Yoshinari N; Udagawa N
PLoS One; 2017; 12(9):e0184904. PubMed ID: 28937990
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of osteoclast bone resorption activity through osteoprotegerin-induced damage of the sealing zone.
Song R; Gu J; Liu X; Zhu J; Wang Q; Gao Q; Zhang J; Cheng L; Tong X; Qi X; Yuan Y; Liu Z
Int J Mol Med; 2014 Sep; 34(3):856-62. PubMed ID: 25017214
[TBL] [Abstract][Full Text] [Related]
18. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
19. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
[TBL] [Abstract][Full Text] [Related]
20. Action of RANKL and OPG for osteoclastogenesis.
Kobayashi Y; Udagawa N; Takahashi N
Crit Rev Eukaryot Gene Expr; 2009; 19(1):61-72. PubMed ID: 19191757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
